Achieve Life Sciences Inc (ACHV)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$6.38-8.67%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
QuarterlyIQ Insights · ACHV
Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.
Figures in millions of None, except per-share and ratios.
| TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenues | ||||||||||||||||
| Revenues | — | — | — | — | — | — | — | 0.0 | 0.0 | — | — | — | — | — | — | — |
| Operating Expenses & Income | ||||||||||||||||
| R&D Expenses | — | — | 22.8 | 15.8 | 30.1 | 24.0 | 6.9 | 9.7 | 5.9 | 3.1 | 0.3 | 25.1 | 46.2 | 55.3 | 39.9 | 21.6 |
| Operating Income | — | — | — | (29.8) | (42.4) | (33.2) | (14.7) | (16.4) | (12.7) | (13.6) | — | — | — | — | (21.1) | (14.7) |
| Earnings from Continuing Operations | ||||||||||||||||
| Interest Expense | — | 0.8 | 2.2 | 2.9 | 1.8 | — | — | — | — | — | — | — | — | — | — | — |
| Interest & Investment Income | 2.8 | 1.5 | 2.4 | 0.8 | 0.2 | 0.0 | 0.1 | 0.2 | 0.2 | 0.0 | 0.2 | 0.1 | 0.0 | 0.2 | 0.3 | 0.2 |
| Net Interest Expenses | — | — | — | 2.0 | 1.6 | — | — | — | — | — | — | — | — | — | — | — |
| Other Non-Operating Income / Expenses | (55.8) | 0.2 | (0.8) | (2.6) | (1.6) | (0.1) | 0.0 | 0.1 | 0.1 | (7.0) | (0.0) | 2.0 | 3.2 | 3.5 | 4.9 | 7.6 |
| Asset Writedown | — | — | — | — | — | — | — | — | — | — | 0.2 | — | — | — | — | — |
| EBT, Incl. Unusual Items | — | (54.6) | (39.8) | (29.8) | (42.4) | (33.2) | (14.7) | (16.4) | (12.7) | (13.6) | — | — | — | — | (21.1) | (14.7) |
| Income Tax Expense | — | — | — | — | — | — | — | — | — | — | 0.0 | 0.0 | 0.0 | — | (3.0) | (3.0) |
| Net Income | ||||||||||||||||
| Net Income | (114.0) | (54.6) | (39.8) | (29.8) | (42.4) | (33.2) | (14.7) | (16.4) | (12.7) | (10.6) | (1.2) | (0.8) | (26.2) | (31.8) | (21.1) | (14.7) |
| Per Share | ||||||||||||||||
| Basic EPS | (1.22) | (1.25) | (1.24) | (1.50) | (4.00) | (4.08) | (5.42) | — | — | — | — | — | — | — | — | — |
| Diluted EPS | (1.22) | (1.25) | (1.24) | (1.50) | (4.00) | (4.08) | (5.42) | — | — | — | — | — | — | — | — | — |
| Basic Weighted Avg Shares | 93.5 | 43.6 | 32.1 | 19.8 | 10.6 | 8.1 | 2.7 | — | — | — | — | — | — | — | — | — |
| Diluted Weighted Avg Shares | 93.5 | 43.6 | 32.1 | 19.8 | 10.6 | 8.1 | 2.7 | — | — | — | — | — | — | — | — | — |
| Supplemental | ||||||||||||||||
| EBITDA | — | — | — | (29.6) | (42.1) | (32.9) | (14.5) | — | — | — | — | — | — | — | — | — |
| EBIT | — | — | — | (29.8) | (42.4) | (33.2) | (14.7) | (16.4) | (12.7) | (13.6) | — | — | — | — | (21.1) | (14.7) |
| Effective Tax Rate | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 14.2% | 20.4% |
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.